Premium
Alterations in chemokine receptor expressions on peripheral blood monocytes in multiple sclerosis and neuromyelitis optica
Author(s) -
Cui Yi Wen,
Kawano Yuji,
Shi Nan,
Masaki Katsuhisa,
Isobe Noriko,
Yonekawa Tomomi,
Matsushita Takuya,
Tateishi Takahisa,
Yamasaki Ryo,
Murai Hiroyuki,
Kira Junichi
Publication year - 2013
Publication title -
clinical and experimental neuroimmunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.297
H-Index - 15
ISSN - 1759-1961
DOI - 10.1111/cen3.12039
Subject(s) - multiple sclerosis , neuromyelitis optica , monocyte , cd16 , medicine , immunology , flow cytometry , chemokine , chemokine receptor , cd64 , prednisolone , ccr2 , immune system , cd8 , cd3
Objectives Human peripheral blood monocytes comprise three different subtypes: CD 14+CD16− (classical type), CD 14 low CD 16+ (non‐classical type) and CD 14+ CD 16+ (intermediate type). These subsets are known to have different functions, but little is known about their roles in multiple sclerosis ( MS ), especially for maintaining remission. We aimed to clarify the alterations in monocyte subsets in patients with MS and neuromyelitis optica ( NMO )/ NMO spectrum disorder ( NMOSD ) in the remission phase. Methods Blood samples were collected from 19 MS patients and 10 NMO / NMOSD patients in the remission phase, and 42 healthy controls ( HC ). The surface expressions of CCR 2, CX 3 CR 1, CD 64 (FcγR1) and CD 62L were analyzed in the monocyte subsets by flow cytometry. Results CCR 2 expression was significantly decreased in classical monocytes from MS patients, regardless of interferon‐β ( IFN ‐β) treatment, but not in those from NMO / NMOSD patients. CX 3 CR 1 expression was also decreased in all monocyte subsets from MS patients receiving IFN ‐β, whereas CX 3 CR 1 expression in classical monocytes was only decreased in NMO / NMOSD patients receiving prednisolone. In NMO / NMOSD patients on prednisolone, the percentages of CD 14+ CD 16+ intermediate monocytes, CD 14 low CD 16+ non‐classical monocytes and CD 64+ CD 14+ CD 16+ monocytes among total monocytes were significantly lower than in HC . CD 62L expression on the monocyte subsets showed no significant differences among the patients and HC . Conclusions Our findings suggest that alterations in chemokine receptor expressions on peripheral blood monocytes can occur in MS and NMO / NMOSD during the remission phase. Down‐modulation of CCR 2 in MS , and CX 3 CR 1 in MS and NMO / NMOSD could partly contribute to sustained remission by preventing monocyte infiltration into the central nervous system.